Nature Communications (Apr 2022)
Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19
- Hengrui Liu,
- Sho Iketani,
- Arie Zask,
- Nisha Khanizeman,
- Eva Bednarova,
- Farhad Forouhar,
- Brandon Fowler,
- Seo Jung Hong,
- Hiroshi Mohri,
- Manoj S. Nair,
- Yaoxing Huang,
- Nicholas E. S. Tay,
- Sumin Lee,
- Charles Karan,
- Samuel J. Resnick,
- Colette Quinn,
- Wenjing Li,
- Henry Shion,
- Xin Xia,
- Jacob D. Daniels,
- Michelle Bartolo-Cruz,
- Marcelo Farina,
- Presha Rajbhandari,
- Christopher Jurtschenko,
- Matthew A. Lauber,
- Thomas McDonald,
- Michael E. Stokes,
- Brett L. Hurst,
- Tomislav Rovis,
- Alejandro Chavez,
- David D. Ho,
- Brent R. Stockwell
Affiliations
- Hengrui Liu
- Department of Chemistry, Columbia University
- Sho Iketani
- Aaron Diamond AIDS Research Center, Columbia University Irving Medical Center
- Arie Zask
- Department of Biological Sciences, Columbia University
- Nisha Khanizeman
- Department of Chemistry, Columbia University
- Eva Bednarova
- Department of Chemistry, Columbia University
- Farhad Forouhar
- Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
- Brandon Fowler
- Department of Chemistry, Columbia University
- Seo Jung Hong
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center
- Hiroshi Mohri
- Aaron Diamond AIDS Research Center, Columbia University Irving Medical Center
- Manoj S. Nair
- Aaron Diamond AIDS Research Center, Columbia University Irving Medical Center
- Yaoxing Huang
- Aaron Diamond AIDS Research Center, Columbia University Irving Medical Center
- Nicholas E. S. Tay
- Department of Chemistry, Columbia University
- Sumin Lee
- Department of Chemistry, Columbia University
- Charles Karan
- Sulzberger Columbia Genome Center, Columbia University
- Samuel J. Resnick
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center
- Colette Quinn
- Waters Corporation
- Wenjing Li
- Waters Corporation
- Henry Shion
- Waters Corporation
- Xin Xia
- Department of Biological Sciences, Columbia University
- Jacob D. Daniels
- Department of Pharmacology and Molecular Therapeutics, Columbia University Irving Medical Center
- Michelle Bartolo-Cruz
- Department of Biological Sciences, Columbia University
- Marcelo Farina
- Department of Biological Sciences, Columbia University
- Presha Rajbhandari
- Department of Biological Sciences, Columbia University
- Christopher Jurtschenko
- Waters Corporation
- Matthew A. Lauber
- Waters Corporation
- Thomas McDonald
- Waters Corporation
- Michael E. Stokes
- Department of Biological Sciences, Columbia University
- Brett L. Hurst
- Institute for Antiviral Research, Utah State University
- Tomislav Rovis
- Department of Chemistry, Columbia University
- Alejandro Chavez
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center
- David D. Ho
- Aaron Diamond AIDS Research Center, Columbia University Irving Medical Center
- Brent R. Stockwell
- Department of Chemistry, Columbia University
- DOI
- https://doi.org/10.1038/s41467-022-29413-2
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 16
Abstract
Small molecule drugs promise to remain a valuable tool in controlling the ongoing COVID-19 pandemic. Here the authors describe optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for potential treatment of COVID-19.
